deepc Enriches Enterprise Health AI Portfolio with Riverain Technologies’ ClearRead™ solutions on deepcOS®

Munich, Germany & Miamisburg, OH, November 17, 2025 — Chest imaging remains one of the most demanding areas in diagnostic radiology. Subtle findings in the lung and mediastinum are often obscured by overlapping anatomy, making early detection both difficult and time-intensive. As imaging demand continues to grow, radiologists need AI support that enhances visibility without disrupting how they work.

To help radiologists see more clearly and report with greater confidence, deepc has integrated Riverain Technologies’ FDA-cleared and CE-marked ClearRead™ CT and ClearRead™ XR into the deepcOS® Enterprise AI Infrastructure.

Transforming Chest Imaging Accuracy and Efficiency

ClearRead™ CT enhances chest CT interpretation through vessel suppression, nodule detection and analysis, and incidental coronary artery calcium (CAC) scoring. Studies have shown it can improve detection of previously missed nodules by 29 percent and reduce reading time by 36 percent, supporting faster, more confident decision-making.^{1, 2}

ClearRead™ XR applies bone suppression and advanced image optimization for chest X-rays, enabling the detection of subtle nodules and pneumothorax that might otherwise go unnoticed. Radiologists have reported 17 percent higher nodule detection, 19 percent faster reads, and greater certainty of search, leading to improved diagnostic confidence and workflow efficiency. ^{3, 4}

Seamless Integration Within deepcOS® Enterprise AI Infrastructure

Both ClearRead™ solutions are fully integrated into the deepcOS® Enterprise AI Infrastructure, allowing hospitals to deploy Riverain’s technologies securely within their existing imaging workflows. Through deepcOS®, radiology teams gain:

• Effortless and interoperable implementation without additional IT overhead or system disruption.
• Centralized governance and monitoring to ensure consistent quality and compliance.
• Scalable orchestration across modalities and sites, ensuring performance under enterprise workloads.
  

This integration reflects deepc’s infrastructure-first approach, connecting best-in-class AI solutions within a unified, secure environment that supports continuous innovation and responsible AI lifecycle management.

Proven Technology from a Market Leader in Thoracic Imaging

Riverain Technologies is recognized globally for its innovation in thoracic imaging and long-standing partnerships with leading healthcare institutions. The ClearRead™ suite, FDA-cleared and CE-marked, has demonstrated clinical and operational impact across diverse healthcare systems and imaging environments. Its availability on deepcOS® extends these benefits to hospitals and networks seeking enterprise-ready AI adoption.

‍

<sub>1. Chorath, K., Tharp, K., Watt, C., Bresnahan, B. W., Medverd, J. R., Cross, N. M., & Chalian, H. (2024, December 4). Unveiling the impact of Riverain's vessel suppression: Breakthrough or bust? [Scientific poster presentation]. RSNA 2024 Annual Meeting, Chicago, IL.​
2. Lo, S. B., Freedman, M. T., Gillis, L. B., White, C. S., & Mun, S. K. (2018). JOURNAL CLUB: Computer-Aided Detection of Lung Nodules on CT With a Computerized Pulmonary Vessel Suppressed Function. American Journal of Roentgenology, 210(3), 480–488. doi: 10.2214/ajr.17.18718.​
3 Freedman, M.T., Lo, S.-C., Siebel, J.C., & Bromley, C.M. (2011). Lung Nodules: Improved Detection with Software That Suppresses the Rib and Clavicle on Chest Radiographs. Radiology, 260(1), 265-273. Doi: 10.1148/radiol.11100153.
4 Riverain Technologies ClearRead +Confirm FDA 510(k) Reader Study Results, 2012.</sub>